ReNerve releases 31 December 2024 Half Year Results

Highlights:
• Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023. Revenue
for 1H FY25 reached A$102,000, a 167% increase from the prior corresponding period.
• Global Expansion: New distribution agreements secured with Accession Medical Supplies (Hong
Kong & Macau) and Union MediScience B.S.C. (Middle East, covering six countries), complementing
existing partnerships in New Zealand and Taiwan.
• Clinical Advancements: The NervAlign® Nerve Guide Matrix demonstrated positive animal study
results, showing comparable efficacy to autologous nerve grafts. A clinical study evaluating the
NervAlign® Nerve Cuff for nerve recovery post nerve repair is ongoing, with data expected in March
2025.
• Successful IPO: Raised $7 million (before costs) and listed on the ASX on 26 November 2024,
providing funds for growth initiatives.
• Surgeon Feedback: Continued positive reception highlights the NervAlign® Nerve Cuff’s benefits in
surgical convenience, patient safety, and efficacy.
• Strong Cash Position: Maintained a cash balance of $6.4 million as of 31 December 2024.